EMEA-001760-PIP01-15-M03 - paediatric investigation plan
Olaratumab
PIPHuman
Eli Lilly & Company Limited
E-mail: eu_paediatric@lilly.com
Tel. +44 (0)1276 483000
P/0112/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan and on granting of a waiver in condition for treatment of soft tissue sarcoma for olaratumab (Lartruvo), (EMEA-001760-PIP01-15-M03)